GleamWall
中文EN

BIAF bioAffinity Technologies, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1712762 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.5%
TTM net income YoY-4.6%
TTM EPS YoY182.9%
Revenue 3-yr CAGR37.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-246.1%
Net margin-278.9%
FCF margin-235.9%
EBITDA margin-239.5%

Returns

ROE-240.5%
ROA-161.4%
ROIC (approx.)-827.2%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets48.2%
Debt / equity0.00x
Current ratio1.51x
Interest coverage-270.95x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.07M$1.51M$1.35M$1.59M$1.45M$1.27M$1.85M$2.21M
R&D expense$389,122$361,575$349,707$374,012$330,589$311,372$367,386$390,658
SG&A expense$2.76M$2.86M$3.24M$3.04M$2.21M$2.21M$2.45M$2.92M
Operating income-$3.51M-$3.33M-$3.62M-$3.14M-$2.29M-$2.52M-$2.63M-$2.95M
Interest expense$10,713$11,688$14,722$13,069$5,358$10,460$15,485$25,045
Pretax income-$5.28M-$3.37M-$3.63M-$3.13M-$5.05M-$4.03M-$2.65M-$2.97M
Income tax———$3,181$3,182$28,984$8,695$0
Net income-$5.28M-$3.37M-$3.63M-$3.14M-$5.05M-$4.06M-$2.66M-$2.97M
EBITDA-$3.44M-$3.27M-$3.50M-$3.01M-$2.18M-$2.40M-$2.47M-$2.79M
EPS (basic)-5.89-0.64-0.81—-71.05-5.07-4.80—
EPS (diluted)-5.89-0.64-0.81—-71.05-5.07-4.80—
Weighted avg. shares (diluted)896,2715.23M4.49M—71,090800,637541,841—
Balance sheet
Cash & equivalents$2.55M$2.43M$3.10M$6.45M$7.67M$802,835$444,706$1.11M
Inventory$108,754$82,378$77,887$53,548$35,234$43,971$38,782$27,608
Current assets$3.83M$3.87M$4.34M$7.57M$8.61M$1.67M$1.86M$2.70M
PP&E, net$362,359$313,708$246,849$265,593$303,122$351,368$382,409$375,385
Goodwill$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M$1.40M
Intangibles$673,056$687,639$702,222$716,806$731,389$745,972$760,556$775,139
Total assets$7.55M$7.62M$7.95M$10.96M$11.55M$4.75M$5.55M$6.51M
Current liabilities$2.53M$2.68M$3.18M$2.91M$2.36M$2.59M$3.42M$3.10M
Short-term debt$160,000———$260,000———
Total liabilities$3.64M$3.85M$4.28M$3.68M$2.64M$6.89M$4.11M$3.91M
Shareholders' equity$3.91M$3.77M$3.65M$7.28M$8.90M-$2.14M$1.44M$2.60M
Shares outstanding1.17M6.78M4.50M299,8263.47M28.46M18.26M519,158
Cash flow statement
Operating cash flow-$3.87M-$3.20M-$3.23M-$2.56M-$2.48M-$2.65M-$1.64M-$1.68M
Capital expenditure$77,050$89,970$5,663$1-$3,646$13,427$50,786$1
Free cash flow-$3.95M-$3.29M-$3.23M-$2.56M-$2.48M-$2.66M-$1.69M-$1.68M
Investing cash flow-$77,050-$89,970-$5,663-$1$3,646-$13,427-$50,786-$1
Financing cash flow$4.07M$2.62M-$118,513$1.34M$9.34M$3.02M$1.03M$2.03M
Depreciation & amortization$66,842$61,556$114,518$123,659$113,360$113,229$154,588$153,632
Stock-based compensation$138,893$784,941$14,340$66,119$67,132$211,607$326,616$234,087

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.